Background Artemisinin-combination therapy (ACT) is recommended as fi rst-line treatment of falciparum malaria throughout the world, and fi xed-dose combinations are preferred by WHO; whether a single gametocytocidal dose of primaquine should be added is unknown. We aimed to compare eff ectiveness of four fi xed-dose ACTs and a loose tablet combination of artesunate and mefl oquine, and assess the addition of a single gametocytocidal dose of primaquine.
Introduction
Artemisinin-based combination therapy (ACT) is recommended by WHO for the treatment of uncomplicated falciparum malaria. 1 The success of this recent policy change will depend on the effi cacy of the combination components, high population coverage, low costs, correct dosing, and ensuring good adherence to prescribed treatment. To improve adherence and acceptability, and prevent one drug being taken without its partner, ACTs are preferably formulated in fi xed-dose combinations. [2] [3] [4] [5] Four fi xed-dose ACTs are now available: two new combinations (artesunate-mefl oquine and artesunateamodiaquine) now join artemether-lumefantrine and dihydroartemisinin-piperaquine.
Artemisinin and its derivatives reduce gametocyte carriage, 6 but they do not prevent transmission from gametocytaemia present at the time of treatment. 7 A single gametocytocidal dose of primaquine was widely recommended in low transmission areas before the introduction of ACTs. 8 With the greater eff ects of artemisinins on gametocyte carriage there has been uncertainty whether primaquine should be added to ACT regimens. 9 This question is of increasing importance as countries move from malaria control to elimination, which will require eff ective, well tolerated medicines and reduction of transmission.
Our aim was to compare the effi cacy of the four available fi xed-dose ACTs and the currently used loose tablet combination of artesunate with mefl oquine and to assess the eff ectiveness of adding a single gametocytocidal dose of primaquine.
Methods

Patients
Between Dec 30, 2008, and March 20, 2009, we recruited patients into our open-label randomised study at three clinics in Rakhine state in western Myanmar (Burma), 2, 3, 4, 10 two clinics in Kachin state in northern Myanmar, and one clinic in Shan state in northeast Myanmar. Patients older than 6 months who weighed more than 5 kg and presented with acute uncomplicated Plasmodium falciparum malaria (parasite density 500-200 000 parasites per μL) or mixed infection were enrolled into the study after fully informed consent was obtained from them or their carer. Patients were excluded if they were pregnant, had severe malaria, had severe acute malnutrition (weight-for-height below 70% of median with or without symmetrical peripheral oedema), had taken antimalarial drugs within the past 48 h, had taken mefl oquine during the past 9 weeks, or had known history of hypersensitivity to any of the study drugs.
Randomisation
After patients were screened and enrolled into the study, they were stratifi ed prospectively into three age groups (1-4 years, 5-14 years, and older than 14 years). Patients were randomly assigned in equal numbers to receive one of the fi ve diff erent treatments. They were then randomly assigned either a single dose of primaquine 0·75 mg base/kg (Government Pharmaceutical Organisation, Bangkok, Thailand) or not. Treatment allocations were put in sealed envelopes in blocks of 50 for each age-group, and random assignment was achieved by patients drawing an envelope from a box after enrolment. When the box was empty, another 50 envelopes were added.
Procedures
For the four fi xed-dose combinations the standard dosage instructions of the manufacturer for weight and age ranges were followed. For the loose tablets regimen of artesunate plus mefl oquine, the target dose was artesunate 4 mg/kg per day for 3 days (total 12 mg/kg) plus mefl oquine 25 mg base/kg on day 0; the number of pills given was rounded off to the nearest quarter of a tablet.
For fi xed dose artesunate-mefl oquine hydrochloride we used 25 mg plus 55 mg or 100 mg plus 220 mg tablets, the target dose was 4·0 mg/kg per day plus 8·8 mg/kg per day for 3 days. For fi xed-dose artemether-lumefantrine we used 20 mg plus 120 mg tablets twice daily for 3 days, the target dose was 3·3 mg/kg per day plus 19·8 mg/kg per day; patients were advised to consume some fatty food (or mothers were encouraged to breastfeed treated infants) before each dose. For fi xed-dose dihydroartemisininpiperaquine we used 40 mg plus 320 mg or 20 mg plus 160 mg tablets, the target dose was 2·5 mg/kg per day plus 20 mg/kg per day. For fi xed dose artesunateamodiaquine we used 25 mg plus 67·5 mg, 50 mg plus 135 mg, or 100 mg plus 270 mg tablets, the target dose was 4 mg/kg per day plus 10·8 mg base/kg per day.
The fi rst dose was taken under supervision. For children, tablets were crushed and syrup was added. All subsequent doses were self administered. Patients received sealed plastic bags containing the remaining doses and were instructed clearly about their subsequent treatment, emphasising the importance of taking primaquine after food, and taking their medicines even when their symptoms had subsided. Patients were asked to return weekly for 9 weeks for assessment, and at any other time if they became ill. Microscopists examining blood fi lms were unaware of treatment allocation. Haemoglobin was measured on day 63.
Patients with recurrent falciparum malaria were treated with artesunate-mefl oquine (loose tablets). Patients who had already received this treatment were given dihydroartemisinin-piperaquine. PCR genotyping was used to distinguish recrudescence from re-infection, by assessment of variable blocks within merozoite surface proteins 1 and 2, and glutamate-rich protein.
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Patients who developed intercurrent Plasmodium vivax or Plasmodium malariae infections received chloroquine (25 mg base/kg) and continued follow-up. If the patients were again positive for P vivax 14 days or later, they were retreated with chloroquine and defi ned as having a new P vivax episode (as a result of treatment failure, relapse, or, less likely, a new infection).
Statistical analysis
A sample size of 160 patients (80 with primaquine) per study group (total 800 patients) allowed a cure rate (100-recrudescence rate) of 95% per group to be estimated with 5% precision, and allowed estimation of eff ectiveness equivalence with a maximum allowable diff erence of 10% (90% power and 95% confi dence) between groups with a follow-up drop-out rate of up to 20%. Treatment groups were compared by two-way factor analysis: ANOVA for continuous variables and multiple logistic regression for categorical data. A test for trend was used for comparisons across age groups. Time-toevent outcomes, including time to fi rst recurrence (vivax or falciparum), time to recrudescence (new infections censored), and time to new infection (recrudescent infections censored) were assessed by the Kaplan-Meier method. Patients lost to follow-up were censored at the last time seen. When failure rates were zero, CIs were estimated with the exact binomial method with the eff ective sample size. All other treatments were compared against the current standard of care, which is artesunate plus mefl oquine (loose tablets), and then against fi xed-dose artesunate-mefl oquine hydrochloride, with the log-rank test, or the Wilcoxon-Breslow test of equality if survival lines crossed. Cox regression was used to quantify risks.
Person-gametocyte weeks (PGW) were defi ned as the number of weeks in which gametocytaemia was patent (excluding at admission) divided by the duration of follow-up, expressed per 1000 person-weeks. The protocol was approved by the Myanmar Department of Health and by the Médecins sans Frontières ethics review board. This study is registered with clinicaltrials. gov, number NCT00902811. 
Role of the funding source
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication. Figure 1 shows the trial profi le. Of the patients screened for malaria, 3416 met the inclusion criteria. Most of the patients that did not agree to participate did so because they lived too far away from the study clinic. 713 of the patients who were randomly assigned to a treatment group were from Rakhine state, 66 were from Kachin state, and 32 were from Shan state. Three patients were excluded after random assignment because they were incorrectly reported as positive for P falciparum on day 7 and so were treated again. Of the 808 eligible patients, 397 (49·1%) also received primaquine (fi gure 1). All patients survived, although 39 (4·9%) did not complete the 63 day follow-up. Baseline characteristics were similar among the fi ve treatment groups (table 1) . Table 2 shows the median (IQR) and range of doses received. All patients cleared parasitaemia by day 7. 69 patients had recurrence of P falciparum within 63 days (table 3) . Recurrence was less common in patients in the fi xeddose artesunate-mefl oquine group than in the fi xed-dose artesunate-amodiaquine group, fi xed-dose artemetherlumefantrine group, and the fi xed-dose dihydroartemisinin-piperaquine group but was not signifi cantly diff erent to that in the loose tablet artesunate-mefl oquine recipients (table 3, fi gure 2). Thus recurrence was less common in the two artesunate-mefl oquine groups combined than in the other ACT groups (for artesunateamodiaquine p<0.0001, for artemether-lumefantrine p=0.0097, and for dihydroartemisinin-piperaquine p=0.02). Recurrence of P falciparum parasitaemia was signifi cantly (p=0·011) more common in children younger than 5 years ( 38 new infections and 20 recrudescent parasitaemias occurred by day 63. Results for nine patients were indeterminate (two artesunate-amodiaquine, three artemether-lumefantrine, three dihydroartemisininpiperaquine, and one loose tablet artesunate-mefl oquine), and data for two patients (one artesunate-amodiaquine and one loose artesunate-mefl oquine) were missing. If indeterminate or missing results are treated as censored fi ndings, then the treatment failure rate after fi xed-dose artesunate-amodiaquine was signifi cantly higher than for the other treatments (for fi xed-dose artesunate-mefl oquine p<0·0001, for artesunate-mefl oquine loose p=0·0018, for artemether-lumefantrine p=0·0013, and for dihydroartemisinin-piperaquine p=0·0012; table 3). If indeterminate or missing results are treated as failures, then failure rates after fi xed-dose artesunate-mefl oquine (0%; 95% CI 0-2·3) were signifi cantly lower than those for other treatments (for artesunate-amodiaquine [11·3%; 95% CI 7·2-17·5] p<0·0001, for artesunate-mefl oquine loose [2·7%; 1·0-7·0] p=0·0355, for artemetherlumefantrine [3·4%; 1·4-7·95] p=0·0191, and for dihydroartemisinin-piperaquine [3·3%; 1·4-7·65] p=0·0207) and failure rates after fi xed-dose artesunate-amodiaquine were signifi cantly higher than with the other regimens; fi xeddose artemether-lumefantrine (p=0·0042), the loose tablet regimen of artesunate-mefl oquine (p=0·0025), fi xed-dose artesunate-mefl oquine (p<0·0001), and fi xed-dose dihydro artemisinin-piperaquine (p=0·004 The risk of new infection was more than three-times higher for patients who received artesunate-amodiaquine compared with the artesunate-mefl oquine groups combined (hazard ratio [HR] 3·2; 95% CI 1·3-8·0; p=0·01) and more than twice that with artemether-lumefantrine (2·6; 1·0-6·6; p=0·04) and dihydroartemisininpiperaquine (2·3; 0·9-6·0; p=0·08).
Results
129 patients (16%) had mixed infections at presentation, and these were more common in children (102 [27%] of 385) than in adults (27 [6%] of 423; risk ratio [RR] 4·2, 95% CI 2·8-6·2; p<0·0001). All patients with mixed infections responded to ACT treatment. 330 patients had P vivax infection during follow-up (fi gure 3): 259 had one episode (68 had mixed infections initially), 55 had two, and three had three. Thus the 330 patients had 404 episodes of P vivax during follow-up. Of the 679 patients presenting with P falciparum infections only, 235 (35%) had subsequent P vivax malaria compared with 95 (74%) of those with mixed infection initially (p<0·0001). Fewer cases of P vivax were recorded in patients who received fi xed-dose artesunate-mefl oquine than in patients who received fi xed-dose artesunateamodiaquine, fi xed-dose artemether-lumefantrine, or the loose tablet regimen of artesunate plus mefl oquine (table 4). The median time to the identifi cation of P vivax was 35 days after fi xed-dose artemether-lumefantrine, 42 days after the loose tablet regimen of artesunate plus mefl oquine, 49 days after fi xed-dose artesunateamodiaquine and fi xed-dose artesunate-mefl oquine, and 56 days after fi xed-dose dihydroartemisinin-piperaquine (p=0·0001). Thus 12 of the 14 cases of recrudescence of P falciparum infection after artesunate-amodiaquine happened before the median time to P vivax relapse for this group (table 2) , which argues against a major eff ect of chloroquine in suppressing recrudescence. The median time to P vivax recurrence was shorter for children aged 0-14 years (42 days; IQR 35-56) than for adults (56; 42-63; p=0·0001). Children were nearly three times more likely to develop intercurrent vivax malaria than were adults, after adjusting for treatment and mixed infections at admission (HR 2·91; 95% CI 2·28-3·70; p<0·0001). Single-dose primaquine did not aff ect P vivax rates (data not shown).
Pooling all recurrences of falciparum or vivax malaria together provided a combined measure of effi cacy and post-treatment prophylaxis, and it also addresses any possible confounding by weak activity of chloroquine against recrudescent P falciparum, because patients were censored at the time of any recurrence of malaria. The day 63 malaria-free rate was highest in the fi xeddose artesunate-mefl oquine (64·3%; 95% CI 56·4-71·1) and the dihydroartemisinin-piperaquine (55·5%, 47·2-63·1) groups. The other three treatment groups had malaria-free rates of less than 50%, and all were signifi cantly worse than fi xed-dose artesunatemefl oquine (artesunate-amodiaquine HR 1·86, 95% CI 1·32-2·62; artemether-lumefantrine 2·46, 1·77-3·43; and the loose tablet regimen of artesunate plus mefl oquine 1·79, 1·28-2·52).
264 patients (33%) presented with patent gametocytaemia, which was more common in children younger than 5 years (46 [53%] of 87) than in children AA 155  155  152  145  138  135  132  128  124  122  AL 162  162  161  154  151  149  147  145  141  139  AM-F 169  169  165  165  165  164  161  160  159  157  AM-L 159  159  155  151  148  146  145  141  140  137  DP 160  160  159  158  156  152  148  146  143  140 Patients with recurrent falciparum (%) 8·4; p<0·0001) . On day 63, eight (1%) of 693 patients were moderately anaemic and 72 (10%) were mildly anaemic. The mean increase of haemoglobin was similar among the fi ve treatment groups, was unaff ected by intercurrent P vivax, but was slightly reduced by primaquine (0·75 g/dL vs 1·04 g/dL; p=0·036; mean diff erence 0·295 g/dL; 95% CI 0·199-0·570).
Number at risk
599 patients (74%) reported adverse events during the study (table 6). 13 patients (1·6%) vomited within the fi rst hour (nine patients within 30 min and four within 30-60 min), four after the loose tablet regimen of artesunate plus mefl oquine, three after artesunate-amodiaquine, two after artemether-lumefantrine, two after fi xed-dose artesunate-mefl oquine, and two after dihydroartemisininpiperaquine. None vomited again after treatment was repeated. Dizziness was more common after fi xed dose artesunate-mefl oquine than after artemether-lumefantrine (RR 1·24; 95% CI 1·03-1·48; p=0·03) and dihydroartemisinin-piperaquine (1·22; 1·02-1·45). Other side-eff ects were less common and were not related to a specifi c treatment. The only side-eff ect attributable to primaquine was abdominal pain (table 7) . There were no cases of urticaria or other potentially serious skin reactions, convulsions, behaviour disturbances, blackwater fever, or severe anaemia (<50 g/L).
Discussion
Control and ultimately elimination of falciparum malaria depends on providing eff ective and well tolerated medicines and minimising transmission. In Myanmar, our large study shows that artesunate-mefl oquine, the fi rst-line treatment in the main study region since 1996, remains very eff ective. The new fi xed-dose artesunateamodiaquine was well tolerated, but was not eff ective enough to be recommended as a fi rst-line treatment. The other available ACTs were all well tolerated and highly eff ective, suggesting good adherence to the prescribed treatments, although only the fi rst dose was observed (ie, the normal context of use). Addition of a single dose of primaquine to ACT regimens has a very large additional eff ect on gametocytaemia, and therefore on malaria transmission potential, making any residual diff erences in gametocyte carriage after the primary infection between the fi ve ACT regimens insignifi cant.
From an operational perspective, fi xed-dose combinations are simple to give and avoid monotherapy, thereby protecting against resistance. Findings from our previous studies have shown that artesunatemefl oquine, the fi rst-line treatment in Myanmar since 1996, is very eff ective.
2-4, 10 The new fi xed-dose artesunatemefl oquine has the greatest effi cacy of all the ACTs assessed. 5 Artesunate-mefl oquine regimens were also associated with greater post-treatment prophylaxis than the other drugs, 12 although diff erences with dihydroartemisinin-piperaquine were not signifi cant. Although artesunate-mefl oquine regimens were associated with slightly more dizziness than were fi xeddose artemether-lumefantrine or dihydro artemisininpiperaquine, 2-4,9,10,13,14 high cure rates argue against a signifi cant eff ect on adherence.
Malaria transmission in Myanmar is seasonal and generally low, but access to eff ective drugs is limited, and the clinical epidemiology is similar to that of higher-transmission settings with a high prevalence of anaemia, high rates of P falciparum gametocytaemia, and substantial discrepancy between cure rates in adults and children. [2] [3] [4] 10 The artemisinin component of ACTs reduces gametocyte carriage, 6, 7, 15 and patients who received artesunate-mefl oquine regimens had the lowest rates of gametocyte carriage after treatment, probably because of the higher dose of the artemisinin derivative compared with artemether-lumefantrine and dihydroartemisinin-piperaquine, and the greater antimalarial eff ect of mefl oquine compared with amodiaquine. The use of ACTs in parts of Rakhine state since 1996 2-4,10 has resulted in a gradual but substantial decrease in falciparum malaria in regions where the drugs are available. The high gametocyte carriage rates probably contribute to diff erences in the eff ect of ACTs on malaria transmission and thus incidence in Myanmar compared with that in other areas in the region, such as the western border of Thailand, where gametocyte carriage rates are low, treatment delays are brief, and, as a result of ACT deployment, falciparum malaria incidence has fallen substantially. 16 Greater coverage of eff ective drug treatments with more potent transmission-blocking activity is expected to result in greater eff ects on malaria incidence.
The 8-aminoquinolines have a rapid and powerful sterilising eff ect on mature gametocytes. 17, 18 Single-dose primaquine has been widely recommended in the past, and used extensively in eradication campaigns; however, its safety profi le has not been well characterised. 19 Primaquine causes abdominal discomfort, particularly if taken on an empty stomach, and potentially serious haemolytic anaemia in patients with glucose-6-phosphate dehydrogenase (G6PD) defi ciency. 20 Single doses have been judged safe, particularly when prevalent genotypes confer mild G6PD defi ciency, although a recent study has challenged this assumption. 21 In our study there were no severe episodes of haemolysis, although we did note a small but signifi cant adverse eff ect on recovery from anaemia. We did not test for G6PD defi ciency, and more frequent measurements of haemoglobin concentrations were not possible.
Mixed P falciparum and P vivax infections were common. 330 patients (41%) had at least one episode of vivax malaria in the 63 day follow-up. The risk was No primaquine Primaquine particularly high in young children-56 children (64%) younger than 5 years had vivax malaria after acute falciparum malaria. This compares with P falciparum recrudescence rates of less than 10%. Treatment of vivax relapses with chloroquine might have provided weak additional activity against P falciparum, suppressing some late recrudescence, particularly for the less eff ective artesunate-amodiaquine. Although because most recrudescence happened within 4 weeks, and most vivax infections were not noted until after 5 weeks, this eff ect is unlikely to have been large. Thus for the four highly eff ective ACT regimens the main clinical problem after eff ective treatment of acute falciparum malaria in Myanmar is recurrent P vivax malaria not P falciparum. 22 Recurrence of vivax malaria was over four times more likely than was recurrence of falciparum malaria, emphasising the public health importance of vivax infections after falciparum malaria. If safe radical treatment was available, then these very high rates would argue for radical treatment of all malaria in this region where mixed infections are so common. This is, to our knowledge, the fi rst comparison of all currently available fi xed-dose artemisinin combination treatments for falciparum malaria. Our fi ndings suggest that artesunate-mefl oquine, artemetherlumefantrine, or dihydroartemisinin-piperaquine are all good treatments of falciparum malaria in Myanmar. The new fi xed dose artesunate-mefl oquine had the highest cure rates, the lowest rates of gametocyte carriage, and the most eff ective suppression of P vivax malaria. Adverse eff ects were generally mild, despite the high doses received by some patients, and did not substantially aff ect adherence. Although giving the entire 25 mg/kg dose of mefl oquine as loose tablets was directly observed, suppression of recurrent vivax malaria was signifi cantly worse than with the fi xed combination, suggesting better absorption of mefl oquine with the latter. 5, 23, 24 The addition of a single gametocytocidal dose of primaquine was well tolerated and highly eff ective and did not cause serious adverse eff ects, although more studies to characterise the safety with diff erent G6PD defi ciency genotypes are needed. The addition of a single dose of primaquine to ACTs could have a major eff ect on malaria transmission from treated patients, and could have a crucial role in elimination programmes.
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